E-LIB Suche - Ergebnisse für: Schleif, W A

1

Caffeine protects Alzheimer's mice against cognitive impair..:

Arendash, G.W. ; Schleif, W. ; Rezai-Zadeh, K....
Neuroscience. 142 (2006) 4 - p. 941-952 , 2006

Link: https://doi.org/10.1016/..

2

Combination Therapy with Zidovudine Prevents Selection of H..:

Staszewski, S. ; Massari, F. E. ; Kober, A....
The Journal of Infectious Diseases. 171 (1995) 5 - p. 1159-1165 , 1995

Link: https://www.jstor.org/st..

3

CLINICAL DEVELOPMENT OF HIV-1 RESISTANCE TO THE VIRAL PROTE..:

Emini, E A ; Deutsch, P ; Schleif, W A.
AIDS. 8 (1994) Supplement 4 - p. S10 , 1994

Link: https://doi.org/10.1097/..

4

L-735,524: An Orally Bioavailable Human Immunodeficiency Vi..:

Vacca, J. P. ; Dorsey, B. D. ; Schleif, W. A....
Proceedings of the National Academy of Sciences of the United States of America. 91 (1994) 9 - p. 4096-4100 , 1994

Link: https://www.jstor.org/st..

5

L-735,524: an orally bioavailable human immunodeficiency vi..:

Vacca, J P ; Dorsey, B D ; Schleif, W A...
Proceedings of the National Academy of Sciences. 91 (1994) 9 - p. 4096-4100 , 1994

Link: https://doi.org/10.1073/..

6

Prevention of HIV-1 infection in chimpanzees by gpl20 V3 do..:

Emini, E. A. ; Schleif, W. A. ; Nunberg, J. H....
Nature. 355 (1992) 6362 - p. 728-730 , 1992

Link: https://doi.org/10.1038/..

7

Pyridinone derivatives: specific human immunodeficiency vir..:

Goldman, M E ; Nunberg, J H ; O'Brien, J A...
Proceedings of the National Academy of Sciences. 88 (1991) 15 - p. 6863-6867 , 1991

Link: https://doi.org/10.1073/..

8

Active human immunodeficiency virus protease is required fo..:

Kohl, N E ; Emini, E A ; Schleif, W A...
Proceedings of the National Academy of Sciences. 85 (1988) 13 - p. 4686-4690 , 1988

Link: https://doi.org/10.1073/..

9

Genetic correlates of in vivo viral resistance to indinavir..:

Condra, J H ; Holder, D J ; Schleif, W A...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC190914. , 1996

Link: http://www.ncbi.nlm.nih...

10

The consequence of passive administration of an anti-human ..:

Conley, A J ; Kessler JA, I I ; Boots, L J...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC190718. , 1996

Link: http://www.ncbi.nlm.nih...

11

L-735,524: an orally bioavailable human immunodeficiency vi..:

Vacca, J P ; Dorsey, B D ; Schleif, W A...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC43730. , 1994

Link: http://www.ncbi.nlm.nih...

12

Susceptibilities of human immunodeficiency virus type 1 enz..:

Byrnes, V W ; Emini, E A ; Schleif, W A...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC188219. , 1994

Link: http://www.ncbi.nlm.nih...

13

A nonnucleoside reverse transcriptase inhibitor active on h..:

Goldman, M E ; O'Brien, J A ; Ruffing, T L...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC187857. , 1993

Link: http://www.ncbi.nlm.nih...

14

Comprehensive mutant enzyme and viral variant assessment of..:

Byrnes, V W ; Sardana, V V ; Schleif, W A...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC188022. , 1993

Link: http://www.ncbi.nlm.nih...

15

Requirement of active human immunodeficiency virus type 1 i..:

LaFemina, R L ; Schneider, C L ; Robbins, H L...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC240448. , 1992

Link: http://www.ncbi.nlm.nih...